SCHEMBL7531974

SCHEMBL7531974

O=C(O)C(=S)CCCC(F)(F)C(F)(F)F

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
TET2 Q6N021 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL865736 0.78 LMNA (0.48) MEN1KMT2A
SCHEMBL2976462 0.75 TET2 (0.42) CA1CA2MEN1KMT2ATET2
SCHEMBL865735 0.73 CA1 (0.35) CA1CA2MEN1KMT2A
SCHEMBL8419645 0.71 ALDH1A1 (0.42) CA1CA2MEN1KMT2A
SCHEMBL5077836 0.71 CA1 (0.37) CA1CA2
SCHEMBL850125 0.70 TSHR (0.55) MEN1KMT2A
SCHEMBL5247491 0.70 TSHR (0.55) MEN1KMT2A
SCHEMBL848884 0.70 TSHR (0.55) MEN1KMT2A
SCHEMBL5247186 0.70 TSHR (0.55) MEN1KMT2A
SCHEMBL3319531 0.69 TET2 (0.41) CA1CA2MEN1KMT2ATET2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0986574-B1 11BETA-ARYL SUBSTITUTED 14,17-ETHANO-OESTRATRIENS, METHOD FOR THE PRODUCTION OF THESE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS. SCHERING AG (DE) 2002-04-03 EP disclosed
EP-0906332-B1 7ALPHA-(5-METHYLAMINOPENTYL)-ESTRATRIENES, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS WHICH CONTAIN SAID 7ALPHA-(5-METHYLAMINOPENTYL)-ESTRATRIENES AND USE THEREOF FOR PRODUCTION OF DRUGS SCHERING AG (DE) 2001-11-28 EP disclosed
US-6288051-B1 ESTROGEN-DEPENDENT BREAST CANCER TREATMENT SCHERING AKTIENGESELLSCHAFT (DE) 2001-09-11 US disclosed
US-6229029-B1 SELECTIVE ESTROGENS EFFECTING BONE, THE CARDIOVASCULAR SYSTEM AND THE CENTRAL NERVOUS SYSTEM; HORMONE REPLACEMENT THERAPY; OSTEOPOROSIS; NO ACTIVITY IN THE UTERUS AND LIVER SCHERING AKTIENGESELLSCHAFT (DE) 2001-05-08 US disclosed
EP-0986574-A1 11$g(b)-ARYL SUBSTITUTED 14,17-ETHANO-OESTRATRIENS, METHOD FOR THE PRODUCTION OF THESE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS. Schering Aktiengesellschaft (DE) 2000-03-22 EP disclosed
WO-1998055499-A1 11β-ARYL SUBSTITUTED 14,17-ETHANO-OESTRATRIENS, METHOD FOR THE PRODUCTION OF THESE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS. SCHERING AKTIENGESELLSCHAFT (DE) 1998-12-10 WO disclosed
EP-0642529-B1 11BETA-SUBSTITUTED 14,17-ETHANOESTRATRIENES, PROCESS FOR PREPARING THESE COMPOUNDS AND THEIR USE FOR PREPARING MEDICAMENTS SCHERING AG (DE) 1996-12-11 EP disclosed
US-5502046-A 11β-substituted 14,17-ethanoestratrienes, process for their production and their use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 1996-03-26 US disclosed
EP-0642529-A1 11-g(b)-SUBSTITUTED 14,17-ETHANOESTRATRIENES, PROCESS FOR PREPARING THESE COMPOUNDS AND THEIR USE FOR PREPARING MEDICAMENTS. SCHERING AG (DE) 1995-03-15 EP disclosed
EP-0546591-A2 11-beta-substituted 14,17-ethanoestratrienes, process for their production and their use in the preparation of medicines SCHERING AKTIENGESELLSCHAFT (DE) 1993-06-16 EP disclosed
WO-1993006124-A1 11β-SUBSTITUTED 14,17-ETHANOESTRATRIENES, PROCESS FOR PREPARING THESE COMPOUNDS AND THEIR USE FOR PREPARING MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 1993-04-01 WO disclosed